There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively[3]. Piroxicam (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration[4]. Piroxicam (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells. In vitro combination of carboplatin and piroxicam produced a more potent antiproliferative effect when compared to single drugs[5].
Piroxicam/吡罗昔康 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Neuro 2A (N-2A) neuroblastoma cells
5 mM
24 hours
To evaluate the protective effects of piroxicam against MPP+ toxicity, results showed piroxicam significantly increased cell viability at 5 mM (from 15±2% to 89±4%)
Neurochem Res. 2009 Feb;34(2):304-10
A-172 cells
3, 14, 30 µM
72 hours
To evaluate the effect of piroxicam on A-172 cells, results showed a protective effect on PBMCs and reduced the fraction of cells in the G2/M phase.
Sci Rep. 2022 Nov 17;12(1):19806
U-87 MG cells
3, 14, 30 µM
72 hours
To evaluate the effect of piroxicam on U-87 MG cells, results showed a protective effect on PBMCs.
Sci Rep. 2022 Nov 17;12(1):19806
Peripheral blood mononuclear cells (PBMCs)
3, 14, 30 µM
72 hours
To evaluate the effect of piroxicam on PBMC proliferation, results showed no adverse effect on proliferation.
Sci Rep. 2022 Nov 17;12(1):19806
Full thickness rat skin
0.5% w/w
8 hours
Assess the permeability of piroxicam through rat skin, with formula F3 showing significantly higher steady-state flux.
Int J Nanomedicine. 2010 Nov 4;5:915-24
Cellulose acetate membrane
0.5% w/w
8 hours
Evaluate the release rate of piroxicam from nanocream, showing that formula F3 released 100% of the drug within 8 hours.
Int J Nanomedicine. 2010 Nov 4;5:915-24
Piroxicam/吡罗昔康 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Dogs
Malignant Mesothelioma
Oral
0.3 mg/kg
Daily (dogs) and every other day (cats), for 4 months
To evaluate the efficacy of piroxicam combined with platinum-based chemotherapy for malignant mesothelioma. Results showed that the combination effectively controlled malignant effusion, with one dog remaining in remission after 3 years, while another dog and a cat died due to disease progression after 8 and 6 months, respectively.
J Exp Clin Cancer Res. 2008 May 19;27(1):6
Sprague-Dawley rats
Carrageenan-induced hind paw edema model
Topical application
0.5% w/w
Single dose, lasting 6 hours
Evaluate the anti-inflammatory and analgesic effects of piroxicam nanocream, with formula F3 showing the highest effects.
Int J Nanomedicine. 2010 Nov 4;5:915-24
Male albino mice
Piroxicam-induced liver and kidney injury model
Administered through drinking water
0.8 mg/kg
Daily administration for 6 weeks
To investigate the side effects of piroxicam on liver and kidney functions and evaluate the mitigating effects of selenium-enriched probiotics. Results showed that piroxicam significantly increased levels of urea, creatinine, bilirubin, SGOT, SGPT, and ALP, while selenium-enriched probiotics (especially BSe50/20/1) significantly improved these parameters.
Inflammopharmacology. 2022 Dec;30(6):2097-2106
Charles Foster rats
Middle cerebral artery occlusion (MCAO) model
Intraperitoneal injection
10 mg/kg
Single dose 30 minutes prior to MCAO
To investigate the effects of Piroxicam on 5-hydroxytryptamine (5-HT) levels and its probable GABA agonism following cerebral ischemia. Results showed that Piroxicam pretreatment significantly decreased extracellular 5-HT release in the ischemic cerebral cortex and striatum, suggesting that Piroxicam may reduce 5-HT release through GABA agonism.
Neural Regen Res. 2015 Sep;10(9):1418-20
IL-10-deficient mice
Piroxicam-accelerated colitis model
Standard chow diet
150 mg/kg
10 days
Piroxicam-induced colitis was associated with significant alterations of the intestinal barrier function, including increased permeability, changes in inflammation-related bioactive lipid mediators, and alterations in mucosal CD4+T lymphocyte subsets.
Int J Mol Sci. 2021 Jul 9;22(14):7387
C57/BL6 male mice
MPTP-induced Parkinson's disease model
Intraperitoneal injection
20 mg/kg
3-day pretreatment, continued until the end of the study
To evaluate the protective effects of piroxicam against MPTP-induced SNc dopaminergic neuron degeneration and loss of locomotive function, results showed piroxicam significantly reversed the losses in SNc tyrosine hydroxylase protein expression, SNc DA concentration and associated anomaly in ambulatory locomotor activity
Neurochem Res. 2009 Feb;34(2):304-10
T-cell receptor alpha chain-deficient mice
Model of synchronized colitis
Oral
200 ppm w/w
14 consecutive days
Piroxicam induced a time-prescribed colitis in the proximal colon and cecum of TCR α-deficient mice. Piroxicam administration induced epithelial hyperplasia, goblet cell loss, and leukocyte infiltration with occasional ulceration. Inflammation was multifocal segmental, with areas of tissue damage in between healthy tissue. In addition, variability in the severity of inflammation was observed among replicate animals and treatments, and the administration of dexamethasone only partially ameliorated inflammation in the proximal colon.
Animal Model Exp Med. 2024 Aug;7(4):533-543
Wistar albino male rats
Piroxicam-induced gastric ulcer and hepato-renal toxicity model
Intraperitoneal injection
7 mg/kg
Once daily for 28 days
To investigate the protective effects of CoQ10 against piroxicam-induced oxidative injury and apoptotic pathways. Results showed that piroxicam caused gastric ulceration and hepato-renal damage, which were significantly mitigated by CoQ10.
United States, California
... 展开 >>
Dr. Michael Dao
Garden Grove, California, United States, 92844
United States, Colorado
Kaiser Permanente Colorado
Denver, Colorado, United States, 80011
United States, Kentucky
Gill Heart Institute
Lexington, Kentucky, United States, 40508
United States, Maryland
IRC Clinics
Towson, Maryland, United States, 21204
United States, Massachusetts
Internal Medicine & Cardiology Associates
Fall River, Massachusetts, United States, 02720
Prima CARE
Fall River, Massachusetts, United States, 02720
United States, Virginia
Carilion Clinic
Christiansburg, Virginia, United States, 24073 收起 <<
Closed Non Comminuted Long Bon... 展开 >>e Fractures 收起 <<
Phase 1
Phase 2
Unknown
February 2016
Egypt
... 展开 >> Anesthesiology Dept., College of Medicine, Mansoura University
Recruiting
Mansoura, DK, Egypt, 050
Sub-Investigator: Salwa Hawas, MD
Principal Investigator: Eiad A Ramzy, MD
Sub-Investigator: Douaa G Diab, MD
Sub-Investigator: Nahla S El Bahnsawy, MD
Sub-Investigator: Hany A Mowafi, MD
Sub-Investigator: Talal A Albrahimi, MD 收起 <<
Israel
... 展开 >> Rambam Health Care Campus
Not yet recruiting
Haifa, Israel
Contact: Lior Lowenstein, MD, MS 972502061434 l_lior@rambam.health.gov.il
Principal Investigator: Susana Mustafa, MD 收起 <<
Poor Metabolizer Due to Cytoch... 展开 >>rome P450 CYP2C9 Variant
Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant 收起 <<
Phase 4
Recruiting
December 2018
Brazil
... 展开 >> Bauru School of Dentistry/USP
Recruiting
Bauru, São Paulo, Brazil, 17012-901
Contact: Adriana M Calvo, PhD 551432358276 birinjela@yahoo.com.br 收起 <<
Brazil
... 展开 >> Pfizer Investigational Site
Salvador, Bahia, Brazil
Pfizer Investigational Site
Goiania, Goias, Brazil
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil, 30130-100
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil, 30130-110
Pfizer Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000
Pfizer Investigational Site
Rio De Janeiro, RJ, Brazil, 20551-030
Pfizer Investigational Site
Porto Alegre, RS, Brazil
Pfizer Investigational Site
São Paulo, SP, Brazil
Pfizer Investigational Site
Sao Paulo, Brazil
Pfizer Investigational Site
São Paulo, Brazil, 04062-003 收起 <<
Tunisia
... 展开 >> Emergency Department of University Hospital of Monastir
Recruiting
Monastir, Tunisia, 5050
Contact: bzeouich nasri, Resident 52919170 ext 00216 medecinasri@gmail.com
Principal Investigator: Nouira Samir, Professor 收起 <<
Hong Kong
... 展开 >> Queen Mary Hospital
Active, not recruiting
Hong Kong, Hong Kong
The Family Planning Association of Hong Kong
Recruiting
Hong Kong, Hong Kong
Contact: Sue Lo, MD, FRCOG 29197726 stlo@famplan.org.hk 收起 <<
搜索
HazMat Fee +
